抗抑郁药物和存活率在基于质瘤A注册的回顾性队列研究中
Sonja Edström1, Barbro Numan Hellquist2, Maria Sandström2
1Department of Clinical Sciences, Neurosciences, Umeå University, Umeå, Sweden.
Neuro-oncology practice
|March 18, 2024
概括
抗抑郁药的使用在恶性质瘤患者中很常见,并且与选择性血清素再吸收抑制剂 (SSRI) 和非SSRI的生存率较差有关. 需要进一步的研究来了解抗抑郁药和质瘤存活率之间的这种关联.
科学领域:
- 神经瘤学神经瘤学
- 临床药理学 临床药理学
- 流行病学 流行病学
背景情况:
- 恶性质瘤患者经常患有抑郁症,并接受抗抑郁药物治疗.
- 抗抑郁药物对质瘤进展和患者存活率的影响尚不清楚.
- 了解这种关系对于优化患者护理和治疗策略至关重要.
研究的目的:
- 为了研究抗抑郁药物使用与被诊断患有恶性质瘤的患者的生存结果之间的关联.
- 确定不同类型的抗抑郁药物 (SSRI与非SSRI) 对质瘤患者的存活率有不同的影响.
主要方法:
- 基于登记册的队列研究使用来自瑞典RISK北方数据库的数据进行.
- 包括1231名患有恶性质瘤 (世卫组织等级2,3和4) 的患者,他们接受过手术.
- 6400个没有质瘤的匹配对照被用于比较.
主要成果:
- 抗抑郁药的使用在质瘤患者 (27%) 中明显比对照组 (16%) 更常见.
- 手术后使用抗抑郁药的治疗与质瘤患者的生存率明显降低有关.
- 无论是SSRI还是非SSRI都显示出与生存的负相关性,危险比率从3.26到7.71不等,取决于质瘤等级和抗抑郁药类型.
结论:
- 这项研究表明,抗抑郁药物治疗与恶性质瘤患者的存活率之间存在负面关联.
- 这些发现表明抗抑郁药可能会对质瘤存活率产生负面影响,但需要进一步研究才能确定因果关系.
- 澄清因果关系对于在质瘤患者中使用抗抑郁药物的临床决策至关重要.
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
228
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
228
01:21Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
01:30Electroconvulsive Therapy
39
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
39
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
384
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
384